News

Posts are organized into categories for ease of navigation:

• Algorithm - developments to the interpretation algorithm implemented in Python.
• Announcement - general news related to the Molecular Oncology Almanac.
• Database - changes and additions to the underlying knowledge base.
• Release - aggregated release notes from GitHub releases (serving as the project changelog).

• Database release 2023-01-05 Categories:  Database, Release

  In this release, we add two recent precision oncology approvals from the FDA.

  Continue reading
• Database release 2022-12-01 Categories:  Database, Release

  In this release, we have removed neoantigen burden as a cataloged feature type and combined Silencing with Knockdown feature types. We additionally expanded upon fields required for each feature type within our S.O.P.

  Continue reading
• Database release 2022-10-06 Categories:  Database, Release

  Added entries:

  • (FDA) FGFR2 rearrangements and sensitivity to futibatinib in intrahepatic cholangiocarcinoma.
  Continue reading
• Database release 2022-09-08 Categories:  Database, Release

  Added entries:

  • (FDA) FGFR1 rearrangements and sensitivity to pemigatinib in myeloid/lymphoid neoplasms.
  Continue reading
• Database release 2022-08-04 Categories:  Database, Release

  Added entries:

  • (FDA) ALK-EML4 and sensitivity to crizotinib in inflammatory myofibroblastic tumors.
  • (Clinical trial) BRCA1 and BRCA2 germline variants and sensitivity to olaparib.
  • (Clinical evidence) BRCA2 copy number deletion and loss-of-function somatic variants and sensitivity to olaparib in uterine leiomyosarcoma.
  • (Clinical evidence) CDKN2A deletion and sensitivity to palbociclib in uterine leiomyosarcoma.
  • (Clinical evidence) MYOCD amplification as a diagnostic for strong smooth muscle differentiation in leiomyosarcoma.
  • (Preclinical) RB1 copy number deletion and somatic variants and sensitivity to olaparib and talazoparib in prostate cancer.
  • (Preclinical) RB1 knockout and resistance to palbociclib in prostate cancer.
  • (Preclinical) USP11 silencing and sensitivity to olaparib in osteosarcoma.
  • (Inferential) ATRX copy number deletions and poor prognosis in leiomyosarcoma.
  • (Inferential) BRCA1 and BRCA2 copy number deletion and loss-of-function somatic variants and sensitivity to PARP inhibition (KU0058684, KU0058948).
  • (Inferential) CDKN2C deletion may confer sensitivity to CDK4/6 inhibitors.
  • (Inferential) MAP2K4 and MAPK7 copy number amplification and not sensitive to chemotherapy as well as poor prognosis in osteosarcoma.
  • (Inferential) PDGFRA copy number amplification and poor prognosis in breast cancer.
  • (Inferential) PTEN copy number deletion and poor prognosis in uterine leiomyosarcoma.
  • (Inferential) PTEN copy number deletion and sensitivity to sapanisertib in combination with alpelisib in uterine leiomyosarcoma.
  Continue reading